Posting of Annual Report and

RNS Number : 4840Z

Syntopix Group plc

14 January 2011

 



Press Release

14 January 2011

Syntopix Group plc

("Syntopix" or "the Company")

Posting of Annual Report and notice of AGM

Syntopix Group plc (AIM:SYN), the company focused on topical antimicrobial innovations for products in the medicine and consumer healthcare markets, confirms that the Annual Report and Accounts for the year ended 31 July 2010, the Notice of the Annual General Meeting and the Form of Proxy were posted to shareholders on 14 December 2010.

The Company's Annual General Meeting is to be held on Thursday 20 January 2011 at the offices of IP Group Plc 24 Cornhill, London, EC3V 3ND.

- Ends -

For further information, please contact:

Syntopix Group plc
Dr Stephen Jones, Chief Executive Officer	[phone]
Tom Bannatyne, Chairman	www.syntopix.com

Zeus Capital Ltd
Alex Clarkson/Tom Rowley	Tel: [phone]
	www.zeuscapital.co.uk

XCAP Securities Plc
John Grant/ David Newton	Tel: [phone]
	www.xcapgroup.co.uk

Media enquiries:

Abchurch Communications
Sarah Hollins / Simone Elviss / Claire Dickinson	Tel: [phone]
[e-mail]	www.abchurch-group.com

Notes to editors

About Syntopix Group

Syntopix is a specialised research and development company, focusing on topical antimicrobial innovations for the cosmetic, consumer healthcare and pharmaceutical markets. The Group was founded in 2003 as a spin-out from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of the world's leading experts in skin microbiology.

Syntopix combines scientific excellence with an understanding of consumer need to identify and develop innovative compounds which have clinical efficacy and proven benefits for the treatment of acne, gingivitis and body odour. 

The Group has a robust research pipeline, with a growing library of over 2,700 compounds (with established safety profiles) profiled both individually and in combination for their antimicrobial activity. The Group, which currently has 12 granted UK patent applications, raised £2 million in March 2010, to undertake clinical studies with its lead compounds and to further develop the pipeline.

Syntopix's shareholders include IP Group plc, The Wellcome Trust Limited, The University of Leeds and Ridings Early Growth Investment Company Limited.  Syntopix joined the AIM market of the London Stock Exchange in March 2006. For more information, please visit our website at www.syntopix.com.

 

END

 

 

NOABIMMTMBBBBJB